Symptomatic SARS-CoV-2 Infection with Ageusia after Two mRNA Vaccine Doses

Int J Environ Res Public Health. 2022 Jan 13;19(2):886. doi: 10.3390/ijerph19020886.

Abstract

To raise awareness about preventive measures in COVID-19 pandemic, even though fully vaccinated. Although recent trials showed high efficacy of vaccines in preventing symptomatic infections, there are some individuals experiencing symptomatic SARS-CoV-2 infection. In this case report, a fully vaccinated young dental practitioner experienced symptomatic SARS-CoV-2 infection 55 days postvaccination with BNT162b2 Pfizer vaccine with evident ageusia. Diagnostic swabs were performed and used for viral genome sequencing. The patient fully recovered 15 days after diagnosis. Loss of smell and taste, together with nasal congestion were the main reported symptoms. The use of personal protective equipment prevented spread of infection in patients and co-workers. With the increase of people being fully vaccinated, it is still necessary to follow infection preventive protocols by correctly applying personal protective equipment. Although high efficacy has been proved, some individuals may still be vulnerable to symptomatic infection and new guidelines and markers should be adopted and investigated to find out patients for whom vaccination may not determine full immunization.

Keywords: COVID-19; SARS-CoV-2; coronavirus; healthcare worker; vaccine.

Publication types

  • Case Reports

MeSH terms

  • Ageusia*
  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19*
  • Dentists
  • Humans
  • Pandemics
  • Professional Role
  • SARS-CoV-2
  • Vaccines, Synthetic
  • mRNA Vaccines

Substances

  • COVID-19 Vaccines
  • Vaccines, Synthetic
  • mRNA Vaccines
  • BNT162 Vaccine